Live Search
 
   

 

Annual Meeting of the GTA
Current Regulatory and Scientific Issues in Genetic Toxicology

May 8-10, 2019
John M. Clayton Hall Conference Center
University of Delaware
Newark, DE

Speakers Presentations

Keynote Speaker:

David Andrews
Sunnybrook Research Institute & University of Toronto

High Content Screening of Primary Cells from Cancer Patients to Decipher Apoptosis, Stress, Quiescence and Immunogenic Responses to Drugs

Presentation may be available after meeting Back to Top

Symposium I: Case studies – Mechanistic Investigations
Genotoxic Impurity Management

Jennifer Cheung
Pfizer

Apoptosis Induction in the In Vitro Micronucleus Assay: A Sheep in Wolf's Clothing

Presentation may be available after meeting Back to Top

dotted line

Steven Bryce
Litron Laboratories

MultiFlow® Aneugen Molecular Initiating Event Assay Suggests Black Cohosh Extract Genotoxicity is the Result of Tubulin Destabilization

Presentation may be available after meeting Back to Top

Bob Young
MilliporeSigma, Bioreliance® Toxicology Testing Services

Para-chloroaniline: Lack of Evidence for Direct-DNA Reactivity

Presentation may be available after meeting

Back to Top

Andrew Goodwin
US FDA/CDER

Assessment of Potentially Genotoxic Impurities: Best Practices for Regulatory Submissions

Presentation may be available after meeting

Back to Top

Krista Dobo
Pfizer

Do My Old (Q)SAR Predictions Need a Face-Lift?

Presentation may be available after meeting

Back to Top

Michelle Kenyon
Pfizer

One Assay, Different Protocols, Conflicting Results……What to Do?

Presentation may be available after meeting

Back to Top

Symposium II: Genetic Toxicology Historical Perspectives
Ames - Past, Present and Future

Errol Zeiger
Independent Consultant

A History of Genetic Toxicology

Presentation may be available after meeting

Back to Top

dotted line

Dan Levy
FDA CFSAN

Calling Ames Assays – IWGT Workgroup Update

Presentation may be available after meeting

Back to Top

Patricia Escobar
Merck Research Laboratories, Merck & Co., Inc.

Update on the OECD Evaluation of the Miniaturized Versions of the Bacterial Reverse Gene Mutation Test

Presentation may be available after meeting

Back to Top

Symposium III: Genetoxicity of Inhaled Compounds

Leslie Recio
Integrated Laboratory Systems

Genotoxicity Assessment of Inhaled Prototype Genotoxic Compounds: 1,3-Butadiene, Ethylene Oxide, Benzene

Presentation may be available after meeting

Back to Top

dotted line

Marianna Gaca
British American Tobacco

Evaluation of a Novel Electronic Nicotine Delivery System

Presentation may be available after meeting

Back to Top

dotted line

Symposium IV: Future Directions

Renato Cardoso
Charles River Laboratories

A more humane approach to genotoxicity evaluation: HepaRG 3D culture and alternatives

Presentation may be available after meeting

Back to Top

dotted line

Stephen Ferguson
NIH/NIEHS

Back to the Future with 3D HepaRG Spheroids

Presentation may be available after meeting

Back to Top

dotted liine

Igor P. Pogribny
NCTR FDA

Role of Transcriptomic and Epigenetic Alterations for In Vitro Carcinogenicity Testing

Presentation may be available after meeting

Back to Top

dotted liine


Tetyana Kobets

NYMC

Detecting NOELs for Preneoplastic Effect (DNA-binding) Produced by DNA-reactive Carcinogens


Presentation may be available after meeting

Back to Top

dotted liine

Symposium V: Genotoxicity of Gene Therapy Modalities

Michal Kosicki
Wellcome Sanger Institute

CRISPR-Cas9 Gene Editing and Off-Target Genomic Instability

Presentation may be available after meeting

Back to Top

dotted line

Mark Sands
Washington University School of Medicine

AAV Vector Insertional Mutagenesis and Tumorigenicity

Presentation may be available after meeting

Back to Top

dotted line

Symposium VI: Clinical Impact of Genotoxicity Testing

Robert W. Sobol
University of Southern Alabama

Advancing Precision Medicine and Inhibitor Discovery by Real-time Measurement of DNA Repair Capacity with Molecular Beacons

Presentation may be available after meeting

Back to Top

dotted line


Tynisha Glover

Johnson & Johnson

Evaluating Carcinogenic Potential of Transformed CAR T cells

Presentation may be available after meeting

Back to Top

dotted line

Stephen Dertinger
Litron Laboratories

Human Blood Micronucleated Reticulocyte and PIG-A Mutation Assays: Overcoming Obstacles, Exploring Use Cases

Presentation may be available after meeting

Back to Top

dotted line

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


dotted line

               Home     |     Who We Are     |     Board of Directors     |     Past Scientific Meetings     |     BOD Meeting Minutes     |     Contact
Who We Are 2019 Scientific Meeting Members Only Membership Application/Renewal Corporate Sponsorship GTA Home Page GTA Home Page Email